Vaxart to Host Third Quarter 2023 Business Update and Financial Results Conference Call on November 2

Rhea-AI Summary

Vaxart, Inc. will provide a business update and report financial results for Q3 2023 on November 2, 2023. Conference call to be held at 4:30 p.m. ET. Investors can submit written questions in advance.

Positive

• Vaxart, Inc. will provide a business update and report financial results for Q3 2023, which could positively impact stock price.

Negative

• None.

Conference call to begin at 4:30 p.m. ET

SOUTH SAN FRANCISCO, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report financial results for the third quarter ended September 30, 2023 after the market close on Thursday, November 2, 2023. The Vaxart senior management team will host a conference call on the same day, beginning at 4:30 p.m. ET.

The conference call can be accessed using the following information:

Webcast: Click here
Date: Thursday, November 2, 2023 – 4:30 p.m. ET
Domestic: (877) 407-0832
International: (201) 689-8433
Conference ID: 13741880

Investors may submit written questions in advance of the conference call to ir@vaxart.com.

A replay of the webcast will be available on the Company’s website at www.vaxart.com following the conclusion of the event.

About Vaxart
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s development programs currently include pill vaccines designed to protect against norovirus, coronavirus, seasonal influenza, and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.

Contacts
Vaxart Media Relations:	Investor Relations:
Mark Herr	Andrew Blazier
Vaxart, Inc.	FINN Partners
mherr@vaxart.com	IR@vaxart.com
(203) 517-8957	(646) 871-8486

FAQ

When will Vaxart, Inc. provide a business update and report financial results for Q3 2023?

Vaxart, Inc. will provide a business update and report financial results for Q3 2023 on November 2, 2023.

What time will the conference call be held?

The conference call will be held at 4:30 p.m. ET.

How can investors submit written questions?

Investors can submit written questions in advance to ir@vaxart.com.